Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

AB Docherty, EM Harrison, CA Green, H Hardwick, R Pius, L Norman, KA Holden, JM Read, F Dondelinger, G Carson, L Merson, J Lee, D Plotkin, L Sigfrid, S Halpin, C Jackson, C Gamble, PW Horby, JS Nguyen-Van-Tam, J DunningPJM Openshaw, JK Baillie, MG Semple

Research output: Working paper/PreprintPreprint


Objective: To characterize the clinical features of patients with severe COVID-19 in the UK.

Design: Prospective observational cohort study with rapid data gathering and near real-time analysis, using a pre-approved questionnaire adopted by the WHO.

Setting: 166 UK hospitals between 6th February and 18th April 2020.

Participants: 16,749 people with COVID-19.

Interventions: No interventions were performed, but with consent samples were taken for research purposes. Many participants were co-enrolled in other interventional studies and clinical trials.

Results: The median age was 72 years [IQR 57, 82; range 0, 104], the median duration of symptoms before admission was 4 days [IQR 1,8] and the median duration of hospital stay was 7 days [IQR 4,12]. The commonest comorbidities were chronic cardiac disease (29%), uncomplicated diabetes (19%), non-asthmatic chronic pulmonary disease (19%) and asthma (14%); 47% had no documented reported comorbidity. Increased age and comorbidities including obesity were associated with a higher probability of mortality. Distinct clusters of symptoms were found: 1. respiratory (cough, sputum, sore throat, runny nose, ear pain, wheeze, and chest pain); 2. systemic (myalgia, joint pain and fatigue); 3. enteric (abdominal pain, vomiting and diarrhoea). Overall, 49% of patients were discharged alive, 33% have died and 17% continued to receive care at date of reporting. 17% required admission to High Dependency or Intensive Care Units; of these, 31% were discharged alive, 45% died and 24% continued to receive care at the reporting date. Of those receiving mechanical ventilation, 20% were discharged alive, 53% died and 27% remained in hospital.

Conclusions: We present the largest detailed description of COVID-19 in Europe, demonstrating the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks.

Trial documentation: Available at https://isaric4c.net/protocols. Ethical approval in England and Wales (13/SC/0149), and Scotland (20/SS/0028). ISRCTN (pending).
Original languageEnglish
Publication statusPublished - 28 Apr 2020


Dive into the research topics of 'Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol'. Together they form a unique fingerprint.

Cite this